Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of a single, under-the-skin dose of
interleukin-7 (IL-7) in HIV infected people currently taking anti-HIV drugs.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)